Direct Selling University’s (DSU) Fall 2025 event was an electrifying blend of innovation, inspiration and industry connection, welcoming hundreds of leaders from across the channel to explore cutting-edge trends and come together to chart the future of the industry.
USANA Health Sciences, Inc. announced its financial results for the third quarter of 2025. Net sales increased 7% year-over-year, reaching $214 million, up from $200 million. The company experienced a net loss, however, of $6.5 million, compared to net earnings of $10.6 million in Q3 2024.
USANA Health Sciences, Inc. announced its financial results for the second quarter of 2025. Net sales were $236 million, representing an 11% growth year-over-year but a 5% decline sequentially.
USANA announced the “elevation of its opportunity,” including updates to its brand story and available incentives. The goal of this new enhancement is to improve tools for attracting and retaining new customers and team members and includes new sales bonuses, milestone bonuses and targeted leadership bonuses.
USANA Health Sciences, Inc. announced the financial results for the first fiscal quarter of 2025. Net sales within the quarter represented a 10% year-over-year growth rate, totaling $250 million versus $228 million in the first quarter of 2024.
USANA Health Sciences, Inc. announced its financial results for the fourth quarter and full year 2024. Total net sales in 2024 were $855 million, down from $921 million in 2023.
USANA Health Sciences, Inc. has acquired a 78.8% controlling ownership stake in Hiya Health Products, LLC. This strategic acquisition is expected to broaden USANA’s reach in the children’s health and wellness market through Hiya’s subscription model.
USANA Health Sciences, Inc. received the award for the Manufacturer of the Year by the Utah Manufacturers Association in the “mega-sized (500+ employees) companies” category. This is the third consecutive year that USANA has been recognized with this honor.
USANA announced its third quarter 2024 financial results. Third quarter net sales were $200 million with a diluted EPS of $0.56, down from $213 million and $0.59 respectively during the previous year’s quarter.
USANA Health Sciences, Inc. reported its financial results for the second quarter of 2024. Net sales for the quarter were $213 million, an 11% decline from the same quarter last year, and a 7% decline sequentially.
USANA Health Sciences, Inc. announced its financial results for the first fiscal quarter of 2024, reporting net sales of $228 million, an 8% decrease from Q1 2023 but a 3% increase sequentially. Diluted EPS was $0.86, down 9% from the same quarter in 2023.
USANA Health Sciences, Inc. announced its fourth quarter and fiscal year 2023 financial results, posting net sales of $921 million in 2023, down from $999 million in fiscal 2022. Diluted EPS in fiscal 2023 totaled $3.30, compared to $3.59 in fiscal 2022.